DR info

臨床試験数 : 6 / 薬物数 : 11 - (DrugBank : 2) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 4

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Blinded CDCA 250 mg TID
   Travere Therapeutics, Inc.
      2020   Phase 3   NCT04270682   United States;
Blood tests
   Sheba Medical Center
      2010   -   NCT01613898   Israel;
CDCA Weight-Based Dose TID
   Travere Therapeutics, Inc.
      2020   Phase 3   NCT04270682   United States;
Chenodeoxycholic acid
   Fujimoto Pharmaceutical Corporation
      2020   Phase 3   JPRN-JapicCTI-205157   Japan;
   National Center for Research Resources (NCRR)
      1996   Phase 2   NCT00004346   United States;
FPF1011
   Fujimoto Pharmaceutical Corporation
      2020   Phase 3   JPRN-JapicCTI-205157   Japan;
Lovastatin
   National Center for Research Resources (NCRR)
      1996   Phase 2   NCT00004346   United States;
Open-Label CDCA 250 mg TID
   Travere Therapeutics, Inc.
      2020   Phase 3   NCT04270682   United States;
Rescue Medication CDCA 250 mg TID
   Travere Therapeutics, Inc.
      2020   Phase 3   NCT04270682   United States;